Preferable II

Personalised Exercise-Oncology for improvement of supportive care: a super umbrella trial to demonstrate the (cost)effectiveness of live-remote exercise in cancer survivors

Latest news

01/05/2023 - News
PREFERABLE-II: Personalised Live – Remote Exercise Oncology to improve supportive care
On 26th April 2023, the PREFERABLE-II project held a one-hour event at the EU Parliament to discuss the implementation of personalised live-remote exercise-oncology for improvement of supportive care. The launch event aimed to present the project and its research goals to policy makers and was attended by medical professionals, research specialists, patient associations, and policy-makers.
26/04/2023 - Event
PREFERABLE II Project Launch Event
On the 26th of April at 11:00 CET - 12:00 CET, the PREFERABLE II Project Launch Event will take place both online and in person at the European Parliament in Brussels. The event is entitled 'The importance of exercise for people living with or beyond cancer'. You can now register to attend this event.
More news

Latest twitter / X

You are invited to the PREFERABLE II
Launch Event in the European Parliament: "The importance of exercise for people living with or beyond cancer" April 26th:
We are happy to announce that our PREFERABLE-II website is live now! Go and have a look at #HorizonEurope #ExerciseOncology
The PREFERABLE II project kicked off November 2022. Clinicians & researchers from around Europe & Australia are excited to start this project on personalized and live-remote exercise for cancer patients to improve supportive care. Follow this feed for updates & more information! PREFERABLE_II photo
More twitter


PREFERABLE II consists of an international consortium of twelve academic partners, one cutting edge game development and software engineering SME, an academic clinical research organisation and one European patient organisation (European Cancer Patient Coalition). The partners are from seven countries: the Netherlands, Germany, Sweden, Portugal, Spain, UK and Australia and are coordinated by the University Medical Center Utrecht, the Netherlands.